RxDoctor Payments DataLook up a doctor →

Jose Fernandez, MD

Neurology · Hattiesburg, MSNPI 1144230491

Payments from drug & device makers

$20,445in general payments, 2019–2025

Across 1,137 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Acadia Pharmaceuticals Inc$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Eisai Inc.$1K
  • AstraZeneca$873
  • Argenx US, Inc.$760
  • plus $13K from 54 others

What the payments were for

  • Speaking & faculty fees$1010%
  • Travel & lodging$2131%
  • Food & beverage$20,01298%
  • Education$1191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)170$2,431
Acadia Pharmaceuticals Inc68$1,271
Teva Pharmaceuticals USA, Inc.62$1,018
Eisai Inc.50$1,006
AstraZeneca(2 entities)41$873
Argenx US, Inc.31$760
SK Life Science, Inc.29$735
Neurocrine Biosciences, Inc.34$703
Novartis37$665
Pfizer55$661
UCB, Inc.31$597
EMD Serono, Inc.35$592
Lilly USA, LLC37$584
Neuronetics, Inc.3$583
Bristol Myers Squibb32$576
Lundbeck LLC32$563
Sunovion Pharmaceuticals Inc.34$499
Genentech USA, Inc.28$439
Sanofi20$431
Amgen(2 entities)24$399
Biogen23$379
Acorda Therapeutics, Inc18$354
TG Therapeutics, Inc.15$288
Otsuka America Pharmaceutical, Inc.12$284
MDD US Operations, LLC13$271
ANI Pharmaceuticals, Inc.13$234
Merz Pharmaceuticals, LLC10$213
Johnson & Johnson(2 entities)18$211
Supernus Pharmaceuticals, Inc.12$198
Grifols USA, LLC9$188
Biohaven Pharmaceuticals, Inc.13$169
Sumitomo Pharma America, Inc.10$162
Biohaven Pharmaceutical Holding Company Ltd.10$148
Alnylam Pharmaceuticals Inc.7$142
Jazz Pharmaceuticals Inc.6$135
GE HealthCare8$133
Kyowa Kirin, Inc.7$130
Avanir Pharmaceuticals, Inc.8$130
Adamas Pharmaceuticals, Inc.7$116
Tanabe Pharma America, Inc.6$113
Octapharma USA, Inc.5$111
CSL Behring7$109
Upsher-smith Laboratories LLC6$84
Daiichi Sankyo Inc.4$79
Vanda Pharmaceuticals Inc.4$77
Catalyst Pharmaceuticals, Inc.4$72
Neurelis, Inc.3$65
Mallinckrodt Enterprises LLC4$64
Akcea Therapeutics, Inc.2$51
Amneal Pharmaceuticals LLC3$48
Greenwich Biosciences, Inc.2$36
Zogenix Inc.2$34
Medtronic2$31
Impel Pharmaceuticals Inc.2$27
Ultragenyx Pharmaceutical Inc.1$24
Promius Pharma LLC1$23
Otsuka Pharmaceutical Development & Commercialization, Inc.1$22
Takeda Pharmaceuticals U.S.A., Inc.1$20
Immedica Pharma US, Inc.1$19
Axsome Therapeutics, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,445 in reported general payments places this provider in the 75th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$529,580
Medicare patients
614
Services billed
68,182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine15$182,465
AptiomEslicarbazepine Acetate99$132,744
Avonex (4 Pack)Interferon Beta-1a16$130,132
Kesimpta PenOfatumumab12$102,730
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$57,290
FycompaPerampanel37$45,937
GlatopaGlatiramer Acetate14$27,300
XcopriCenobamate23$25,746
Oxcarbazepine415$12,717
Levetiracetam489$10,807
Gabapentin510$8,112
Aimovig AutoinjectorErenumab-Aooe11$7,309
NamzaricMemantine Hcl/Donepezil Hcl12$6,664
DepakoteDivalproex Sodium11$6,566
Rivastigmine52$5,929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$1,018$182,46515 claims
Sunovion Pharmaceuticals Inc.Aptiom$499$132,74499 claims
BiogenAvonex (4 Pack)$379$130,13216 claims
Grifols USA, LLCGamunex-C$188$57,29012 claims
Eisai Inc.Fycompa$1,006$45,93737 claims
SK Life Science, Inc.Xcopri$735$25,74623 claims
AbbVieNamzaric$2,431$6,66412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 111 neurology providers in Mississippi.

Other neurology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →